EWP
CYTK icon

Elevation Wealth Partners’s Cytokinetics CYTK Stock Holding History

Elevation Wealth Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.3K Buy
+74
New +$5.31K ﹤0.01% 953
2026
Q1 		– Sell
-65
Closed -$4.13K – 1091
2025
Q4 		$4.13K Buy
+65
New +$4.04K ﹤0.01% 671

Other funds holding CYTK

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Elevation Wealth Partners's CYTK Position: Q2 2026 in Review

Elevation Wealth Partners opened a new position in Cytokinetics (CYTK) in Q2 2026: 74 shares worth $6.3K. The stake represents ﹤0.01% of the portfolio and ranks #953 among its holdings. This is a return to the name: Elevation Wealth Partners previously reported a position in CYTK as recently as Q4 2025.

Elevation Wealth Partners first reported a position in CYTK in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Elevation Wealth Partners held 74 shares of Cytokinetics worth $6.3K as of Q2 2026.
  • Cytokinetics was a new Elevation Wealth Partners position in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #953 holding.
  • Elevation Wealth Partners first reported a position in Cytokinetics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.